Elypta, a Swedish company using metabolism-based liquid biopsy for early detection of cancer, appoints Dr. Eva Pisa to Board of Directors
Stockholm, May 7, 2024: Elypta, a Swedish cancer detection company aiming to commercialize the first metabolism-based liquid biopsy for early detection of cancer, today announced the appointment of Dr. Eva Pisa to its Board of Directors.“I am very much looking forward to working with the team at Elypta in the exciting field of early cancer detection. The team is working on a mass-spectrometer based detection platform where I see a great opportunity as the technology expands into routine use,” says Dr. Pisa. “I am pleased that Dr Eva Pisa has decided to join the board of Elypta. With her